When searching for Aztreonam Avibactam injection uses, it is important to understand that the combination is not simply a conventional antibiotic with a single universal indication. Aztreonam and avibactam have complementary functions, and their clinical role depends on the infecting organism, resistance mechanism, susceptibility results, infection site, and the specific product’s approved indication.
Aztreonam is a monobactam antibiotic, while avibactam is a β-lactamase inhibitor. Together, they have particular relevance in infections involving resistant Gram-negative bacteria, especially when metallo-β-lactamase (MBL) production occurs alongside other β-lactamases.
Where Is Aztreonam Avibactam Injection Used?
The clinical use of an Aztreonam Avibactam injection depends on the regulatory approval applicable to the product and the patient’s clinical circumstances.
For example, the FDA-approved labeling for EMBLAVEO states that, in combination with metronidazole, it is indicated in adults with complicated intra-abdominal infections caused by designated susceptible Gram-negative microorganisms when there are limited or no alternative treatment options.
The organisms listed in that labeling include susceptible strains of:
- Escherichia coli
- Klebsiella pneumoniae
- Klebsiella oxytoca
- Enterobacter cloacae complex
- Citrobacter freundii complex
- Serratia marcescens
This does not mean every infection caused by these organisms should automatically be treated with aztreonam-avibactam. Susceptibility and the patient’s clinical situation remain important.
Why Is Aztreonam Avibactam Important for Resistant Bacteria?
The combination has attracted attention because some Gram-negative bacteria produce multiple β-lactamases at the same time.
One particularly important example is an organism producing a metallo-β-lactamase such as NDM.
NDM can hydrolyze many β-lactam antibiotics but does not efficiently hydrolyze aztreonam. However, NDM-producing bacteria can also produce serine β-lactamases such as ESBLs or AmpC enzymes, which can hydrolyze aztreonam.
This creates a two-part resistance problem.
Aztreonam provides the antibacterial component and has relative stability against MBL-mediated hydrolysis.
Avibactam inhibits several susceptible serine β-lactamases that may otherwise compromise aztreonam.
The combination therefore addresses complementary parts of the resistance mechanism.
Aztreonam Avibactam Injection Uses in NDM-Producing Enterobacterales
One of the most important areas of interest for this combination is NDM-producing Enterobacterales.
NDM is a metallo-β-lactamase associated with resistance to many β-lactam antibiotics.
The 2026 IDSA guidance identifies aztreonam-avibactam as a preferred treatment option for infections caused by NDM-producing Enterobacterales, alongside cefiderocol. The guidance explains that aztreonam remains stable against NDM-mediated hydrolysis while avibactam inhibits susceptible serine β-lactamases frequently produced alongside NDM.
This is an important distinction:
Avibactam does not inhibit NDM directly.
Instead, it helps protect aztreonam from other β-lactamases that may be present in the same bacterial isolate.
Aztreonam Avibactam and MBL-Producing Bacteria
Metallo-β-lactamases are an important mechanism of β-lactam resistance.
Common examples include:
- NDM
- VIM
- IMP
These enzymes can hydrolyze many β-lactam antibiotics.
Aztreonam has a different profile because it is relatively stable against hydrolysis by MBLs.
However, MBL-producing organisms may contain additional resistance mechanisms.
For example:
MBL → affects many β-lactams
ESBL/AmpC → can affect aztreonam
Avibactam → inhibits susceptible ESBL/AmpC
Aztreonam → remains available to act on its bacterial target
This complementary mechanism is central to the scientific rationale behind the combination.
Aztreonam Avibactam Injection Uses in Complicated Intra-Abdominal Infections
A specific approved use of aztreonam-avibactam is in combination with metronidazole for complicated intra-abdominal infections in adults when there are limited or no alternative options and the causative Gram-negative organisms are susceptible.
Complicated intra-abdominal infections can involve multiple organisms, which is why the labeled regimen combines aztreonam-avibactam with metronidazole.
The FDA labeling specifies the approved population, organisms and clinical circumstances rather than recommending the combination for every intra-abdominal infection.
Role in Carbapenem-Resistant Gram-Negative Infections
Another important context is carbapenem-resistant Enterobacterales (CRE).
Carbapenem resistance can result from different mechanisms, including production of carbapenemases.
The appropriate antimicrobial option depends on which carbapenemase or other resistance mechanism is present.
The 2026 IDSA guidance discusses aztreonam-avibactam among the newer β-lactam agents used in selected CRE infections, with the specific recommendation depending on the resistance phenotype and infection type.
This is why the phrase “carbapenem-resistant infection” alone does not provide enough information to select treatment.
The bacterial resistance mechanism matters.
What Does the Injection Contain?
A commonly referenced fixed-dose formulation contains:
| Component | Amount per vial | Function |
|---|---|---|
| Aztreonam | 1.5 g | β-lactam antibacterial |
| Avibactam | 0.5 g | β-lactamase inhibitor |
| Total | 2 g | Fixed-dose combination |
The FDA labeling for EMBLAVEO describes a vial containing 1.5 g aztreonam and 0.5 g avibactam, supplied as a sterile lyophilized powder for reconstitution and intravenous use.
Product composition and administration instructions should always be checked against the applicable product information.
How Does the Combination Work?
The activity of the combination becomes easier to understand by separating the two components.
Aztreonam
Aztreonam is a monobactam β-lactam antibiotic.
It acts on bacterial cell-wall synthesis by binding to its bacterial target, including PBP3.
Its relative stability against MBL-mediated hydrolysis makes it relevant to MBL-producing organisms.
Avibactam
Avibactam is a β-lactamase inhibitor.
It inhibits several susceptible serine β-lactamases, including many class A and class C enzymes and selected class D enzymes.
It does not directly inhibit MBLs.
Together
The two components provide complementary activity:
Aztreonam → antibacterial activity
Avibactam → inhibition of susceptible β-lactamases
This is the central mechanism behind the combination.
Is Aztreonam Avibactam Used for Every Resistant Infection?
No.
A resistant bacterial infection does not automatically mean that aztreonam-avibactam is appropriate.
Treatment decisions depend on factors such as:
- Bacterial species
- Resistance mechanism
- Antimicrobial susceptibility testing
- Site of infection
- Severity of illness
- Previous antimicrobial exposure
- Patient-specific factors
- Local antimicrobial resistance patterns
- Applicable clinical guidelines
The FDA labeling also states that the product should be used only for infections that are proven or strongly suspected to be caused by susceptible bacteria, with culture and susceptibility information considered when available.
Why Is Susceptibility Testing Important?
The presence of a resistance gene or enzyme does not always tell the complete susceptibility story.
Bacteria can carry multiple resistance mechanisms, and resistance can vary between isolates of the same species.
For this reason, microbiology laboratories use antimicrobial susceptibility testing to determine whether an organism is susceptible to a particular agent.
FDA has also established susceptibility testing information for aztreonam-avibactam against Enterobacterales, including recognized MIC and disk-diffusion standards.
This makes laboratory testing an important part of evaluating potential treatment.
Aztreonam + Avibactam Injection: What Makes the Combination Different?
The combination is different from simply adding another antibiotic to a treatment regimen.
Its design is based on the interaction between:
Bacterial resistance mechanism + aztreonam stability + β-lactamase inhibition
Aztreonam is relatively stable against MBLs, but can be affected by other β-lactamases.
Avibactam inhibits several of those susceptible enzymes.
That relationship explains why the combination has particular relevance in certain multidrug-resistant Gram-negative infections.
Meblanios and Aztreonam Avibactam Injection
Meblanios is an aztreonam-avibactam injectable formulation developed by AIONIOS Pharma.
The formulation contains:
Aztreonam 1500 mg + Avibactam 500 mg
This composition combines the antibacterial activity of aztreonam with the β-lactamase-inhibiting activity of avibactam.
For healthcare professionals evaluating an aztreonam-avibactam product, product-specific information, susceptibility results, clinical assessment and applicable treatment guidance should be considered.
Quick Summary of Aztreonam Avibactam Injection Uses
The combination can be relevant in several clinical and microbiological contexts, including:
- Selected complicated intra-abdominal infections under approved product indications
- Infections caused by susceptible resistant Gram-negative organisms
- NDM-producing Enterobacterales
- Selected carbapenem-resistant Enterobacterales infections
- Situations where β-lactamase-mediated resistance is an important consideration
The exact indication and treatment approach depend on the specific product, regulatory jurisdiction, organism, susceptibility profile and patient.
Frequently Asked Questions
What are Aztreonam Avibactam injection uses?
Uses depend on the specific product and regulatory approval. The combination has an approved role in certain complicated intra-abdominal infections and is also an important treatment option discussed in current guidance for selected resistant Gram-negative infections, particularly NDM-producing Enterobacterales.
Is Aztreonam Avibactam an injection?
Yes. Approved aztreonam-avibactam products are supplied for intravenous administration. The FDA-described EMBLAVEO formulation is supplied as a powder requiring reconstitution and dilution for intravenous use.
What is the composition of Aztreonam Avibactam injection?
A commonly referenced formulation contains 1.5 g aztreonam and 0.5 g avibactam per vial.
Is Aztreonam Avibactam used for MBL infections?
The combination is particularly relevant to certain MBL-producing organisms because aztreonam is relatively stable against MBL-mediated hydrolysis while avibactam can inhibit susceptible serine β-lactamases that may be produced alongside an MBL.
Does Avibactam kill bacteria?
Avibactam is not the primary antibacterial component. It is a β-lactamase inhibitor that protects the partner β-lactam antibiotic from susceptible β-lactamases.
Is Aztreonam Avibactam suitable for every antibiotic-resistant infection?
No. The choice of therapy depends on the organism, resistance mechanism, susceptibility testing, infection site, patient factors and applicable clinical guidance.
Conclusion
Aztreonam Avibactam injection uses are best understood through the resistance mechanisms the combination is designed to address.
Aztreonam provides antibacterial activity and has relative stability against metallo-β-lactamase-mediated hydrolysis. Avibactam inhibits several susceptible serine β-lactamases that can otherwise compromise aztreonam.
This complementary mechanism is particularly relevant to certain resistant Gram-negative infections, including infections caused by NDM-producing Enterobacterales. Current IDSA guidance specifically addresses aztreonam-avibactam in this setting.
At the same time, the approved indication of a specific aztreonam-avibactam product must be distinguished from broader clinical applications discussed in guidelines and research. Treatment should be based on microbiological susceptibility, clinical assessment and applicable prescribing information.
Medical Disclaimer: This article is intended for educational purposes only and does not replace professional medical advice. Antibiotic selection, dosage and administration should be determined by qualified healthcare professionals based on the patient’s condition, culture and susceptibility results, product information and applicable clinical guidelines.